16.42 USD
↗ 0.60 (3.79%)AT CLOSE (11:59 AM EDT)
Aurinia Pharmaceuticals Inc
AUPHNASDAQ • USD
16.43
↗ 0.01 (0.03%)
POST MARKET (AS OF 07:47 PM EDT)
Post Market
AS OF 07:47 PM EDT
16.43
↗ 0.01 (0.03%)
Market: CLOSED
Open?$15.93
High?$16.44
Low?$15.89
Prev. Close?$15.82
Volume?1.2M
Avg. Volume?1.1M
VWAP?$16.11
Rel. Volume?1.12x
Bid / Ask
Bid?$16.35 × 200
Ask?$16.45 × 200
Spread?$0.10
Midpoint?$16.40
Valuation & Ratios
Market Cap?2.1B
Shares Out?133.0M
Float?110.8M
Float %?84.2%
P/E Ratio?7.33
P/B Ratio?3.62
EPS?$2.16
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?5.25Strong
Quick Ratio?4.76Strong
Cash Ratio?0.86Adequate
Debt/Equity?0.12Low
ValuationFAIRLY VALUED
Score67/100
P/E?7.3CHEAP▾
P/B?3.62FAIR▾
P/S?7.43HIGH▾
P/FCF?15.5CHEAP▾
EV/EBITDA?17.9FAIR▾
EV/Sales?7.39HIGH▾
Returns & Efficiency
ROE?49.4%STRONG▾
ROA?38.2%STRONG▾
Cash Flow & Enterprise
FCF?$135.4M
Enterprise Value?$2.1B
News
Profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Employees
128
Market Cap
2.1B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2009-10-21
Address
#140, 14315 - 118 AVENUE
EDMONTON, A0 T5L 4S6
Phone: 250-744-2487
EDMONTON, A0 T5L 4S6
Phone: 250-744-2487